Our Healthy Rewards Program is getting an update in September! For a sneak peek of all the changes - including new rewards and ways to redeem them - please click here.
¡Nuestro Programa Healthy Rewards tendrá su actualización en septiembre! Para ver un adelanto de todos los cambios, incluyendo nuevas recompensas y formas de canjearlas, haz clic aquí.
Change in Preferred Drug List Status for Stimulants and Related Agents Drug Class
Date: August 12, 2025
Attention: All Providers
Effective dates: August 11 and 18, 2025
Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective August 11 and 18, 2025, the Texas Health and Human Services Commission (HHSC) removed the non-preferred status from generic methylphenidate patch products and certain methylphenidate products on the preferred drug list (PDL).
This change is in response to:
A reported shortage of the active ingredient in Daytrana patch products, as reported by the manufacturer, Noven, and,
Ongoing drug shortages of various brand and generic methylphenidate products.
Impacted Medication
Type of Change
Effective Date
METHYLPHENIDATE 10 MG/9HR PTCH
Generic now preferred
August 11, 2025
METHYLPHENIDATE 15 MG/9HR PTCH
Generic now preferred
August 11, 2025
METHYLPHENIDATE 20 MG/9HR PTCH
Generic now preferred
August 11, 2025
METHYLPHENIDATE 30 MG/9HR PTCH
Generic now preferred
August 11, 2025
COTEMPLA XR-ODT 8.6 MG TABLET
Brand now preferred
August 18, 2025
COTEMPLA XR-ODT 17.3 MG TABLET
Brand now preferred
August 18, 2025
COTEMPLA XR-ODT 25.9 MG TABLET
Brand now preferred
August 18, 2025
QUILLICHEW ER 20 MG CHEW TAB
Brand now preferred
August 18, 2025
QUILLICHEW ER 30 MG CHEW TAB
Brand now preferred
August 18, 2025
QUILLICHEW ER 40 MG CHEW TAB
Generic now preferred
August 18, 2025
METHYLPHENIDATE ER 10 MG TAB
Generic now preferred
August 18, 2025
METHYLPHENIDATE ER 20 MG TAB
Generic now preferred
August 18, 2025
How this impacts providers: The change will allow providers to prescribe the generic without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.
Next step for providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.